Prelude Therapeutics Inc. (PRLD), Friday announced clinical data from the ongoing Phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader, designed to treat cancer patients with a SMARCA4 mutation.
The findings disclosed encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer and esophageal cancer during early PRT3789 monotherapy dose escalation.
Also, among the 26 advanced, heavily pre-treated NSCLC or esophageal patients who were evaluable for efficacy, seven experienced tumor shrinkage.
Currently, Prelude's stock is dropping 27.85 percent, to $3.48 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.